Medical - Devices
Compare Stocks
4 / 10Stock Comparison
AVNS vs SYK vs ZBH vs MMSI
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Devices
Medical - Instruments & Supplies
AVNS vs SYK vs ZBH vs MMSI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $1.16B | $112.69B | $16.32B | $3.72B |
| Revenue (TTM) | $716M | $25.12B | $8.41B | $1.54B |
| Net Income (TTM) | $-69M | $3.25B | $761M | $139M |
| Gross Margin | 49.4% | 63.5% | 70.0% | 48.7% |
| Operating Margin | -8.4% | 22.4% | 15.6% | 12.2% |
| Forward P/E | 24.8x | 19.6x | 9.8x | 15.5x |
| Total Debt | $129M | $14.86B | $7.52B | $898M |
| Cash & Equiv. | $90M | $4.01B | $592M | $449M |
AVNS vs SYK vs ZBH vs MMSI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Avanos Medical, Inc. (AVNS) | 100 | 85.2 | -14.8% |
| Stryker Corporation (SYK) | 100 | 150.3 | +50.3% |
| Zimmer Biomet Holdi… (ZBH) | 100 | 68.0 | -32.0% |
| Merit Medical Syste… (MMSI) | 100 | 138.5 | +38.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AVNS vs SYK vs ZBH vs MMSI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AVNS is the #2 pick in this set and the best alternative if momentum is your priority.
- +96.9% vs MMSI's -33.8%
SYK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 34 yrs, beta 0.55, yield 1.1%
- Rev growth 11.2%, EPS growth 8.2%, 3Y rev CAGR 10.8%
- 12.9% margin vs AVNS's -9.7%
- Beta 0.55 vs AVNS's 1.54
ZBH is the clearest fit if your priority is defensive.
- Beta 0.65, yield 1.1%, current ratio 1.98x
- Lower P/E (9.8x vs 15.5x)
MMSI is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 214.6% 10Y total return vs SYK's 187.1%
- Lower volatility, beta 0.71, Low D/E 56.7%, current ratio 4.34x
- 11.7% revenue growth vs AVNS's 1.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.7% revenue growth vs AVNS's 1.9% | |
| Value | Lower P/E (9.8x vs 15.5x) | |
| Quality / Margins | 12.9% margin vs AVNS's -9.7% | |
| Stability / Safety | Beta 0.55 vs AVNS's 1.54 | |
| Dividends | 1.1% yield, 34-year raise streak, vs ZBH's 1.1%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +96.9% vs MMSI's -33.8% | |
| Efficiency (ROA) | 6.9% ROA vs AVNS's -6.6%, ROIC 11.4% vs -5.4% |
AVNS vs SYK vs ZBH vs MMSI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
AVNS vs SYK vs ZBH vs MMSI — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SYK leads in 2 of 6 categories
ZBH leads 1 • AVNS leads 1 • MMSI leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
SYK leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SYK is the larger business by revenue, generating $25.1B annually — 35.1x AVNS's $716M. SYK is the more profitable business, keeping 12.9% of every revenue dollar as net income compared to AVNS's -9.7%. On growth, SYK holds the edge at +11.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $716M | $25.1B | $8.4B | $1.5B |
| EBITDAEarnings before interest/tax | -$21M | $6.3B | $2.3B | $290M |
| Net IncomeAfter-tax profit | -$69M | $3.2B | $761M | $139M |
| Free Cash FlowCash after capex | $24M | $4.3B | $1.8B | $274M |
| Gross MarginGross profit ÷ Revenue | +49.4% | +63.5% | +70.0% | +48.7% |
| Operating MarginEBIT ÷ Revenue | -8.4% | +22.4% | +15.6% | +12.2% |
| Net MarginNet income ÷ Revenue | -9.7% | +12.9% | +9.1% | +9.0% |
| FCF MarginFCF ÷ Revenue | +3.4% | +17.1% | +21.8% | +17.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +8.8% | +11.4% | +9.3% | +7.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -21.4% | +56.0% | +34.1% | +38.8% |
Valuation Metrics
ZBH leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 23.5x trailing earnings, ZBH trades at a 33% valuation discount to SYK's 35.0x P/E. On an enterprise value basis, ZBH's 9.5x EV/EBITDA is more attractive than SYK's 20.3x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $1.2B | $112.7B | $16.3B | $3.7B |
| Enterprise ValueMkt cap + debt − cash | $1.2B | $123.5B | $23.3B | $4.2B |
| Trailing P/EPrice ÷ TTM EPS | -16.97x | 35.03x | 23.48x | 29.26x |
| Forward P/EPrice ÷ next-FY EPS est. | 24.77x | 19.62x | 9.83x | 15.46x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.36x | — | — |
| EV / EBITDAEnterprise value multiple | — | 20.31x | 9.47x | 13.06x |
| Price / SalesMarket cap ÷ Revenue | 1.65x | 4.49x | 1.98x | 2.45x |
| Price / BookPrice ÷ Book value/share | 1.48x | 5.02x | 1.30x | 2.38x |
| Price / FCFMarket cap ÷ FCF | 26.91x | 26.31x | 11.09x | 17.24x |
Profitability & Efficiency
SYK leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-9 for AVNS. AVNS carries lower financial leverage with a 0.17x debt-to-equity ratio, signaling a more conservative balance sheet compared to SYK's 0.66x. On the Piotroski fundamental quality scale (0–9), SYK scores 6/9 vs ZBH's 5/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -8.9% | +15.0% | +5.8% | +8.9% |
| ROA (TTM)Return on assets | -6.6% | +6.9% | +3.3% | +5.2% |
| ROICReturn on invested capital | -5.4% | +11.4% | +5.4% | +7.2% |
| ROCEReturn on capital employed | -6.5% | +13.0% | +6.9% | +7.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.17x | 0.66x | 0.59x | 0.57x |
| Net DebtTotal debt minus cash | $39M | $10.8B | $6.9B | $450M |
| Cash & Equiv.Liquid assets | $90M | $4.0B | $592M | $449M |
| Total DebtShort + long-term debt | $129M | $14.9B | $7.5B | $898M |
| Interest CoverageEBIT ÷ Interest expense | -16.71x | 6.72x | 4.08x | 10.74x |
Total Returns (Dividends Reinvested)
AVNS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SYK five years ago would be worth $12,152 today (with dividends reinvested), compared to $5,268 for ZBH. Over the past 12 months, AVNS leads with a +96.9% total return vs MMSI's -33.8%. The 3-year compound annual growth rate (CAGR) favors AVNS at 1.8% vs ZBH's -14.4% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +121.6% | -15.2% | -7.1% | -27.9% |
| 1-Year ReturnPast 12 months | +96.9% | -22.5% | -10.4% | -33.8% |
| 3-Year ReturnCumulative with dividends | +5.6% | +5.5% | -37.2% | -26.5% |
| 5-Year ReturnCumulative with dividends | -39.8% | +21.5% | -47.3% | -3.6% |
| 10-Year ReturnCumulative with dividends | -17.0% | +187.1% | -17.8% | +214.6% |
| CAGR (3Y)Annualised 3-year return | +1.8% | +1.8% | -14.4% | -9.8% |
Risk & Volatility
Evenly matched — AVNS and SYK each lead in 1 of 2 comparable metrics.
Risk & Volatility
SYK is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than AVNS's 1.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AVNS currently trades 99.9% from its 52-week high vs MMSI's 62.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.54x | 0.55x | 0.65x | 0.71x |
| 52-Week HighHighest price in past year | $24.80 | $404.87 | $108.29 | $100.19 |
| 52-Week LowLowest price in past year | $9.30 | $289.91 | $79.83 | $59.74 |
| % of 52W HighCurrent price vs 52-week peak | +99.9% | +72.7% | +77.0% | +62.2% |
| RSI (14)Momentum oscillator 0–100 | 90.8 | 24.3 | 34.3 | 34.9 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 2.1M | 2.2M | 769K |
Analyst Outlook
Evenly matched — SYK and ZBH each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: AVNS as "Hold", SYK as "Buy", ZBH as "Hold", MMSI as "Buy". Consensus price targets imply 52.4% upside for MMSI (target: $95) vs -7.1% for AVNS (target: $23). For income investors, ZBH offers the higher dividend yield at 1.15% vs SYK's 1.14%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $23.00 | $403.69 | $97.90 | $95.00 |
| # AnalystsCovering analysts | 8 | 50 | 42 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | +1.1% | +1.1% | — |
| Dividend StreakConsecutive years of raises | 1 | 34 | 0 | — |
| Dividend / ShareAnnual DPS | — | $3.36 | $0.96 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.3% | 0.0% | +3.0% | 0.0% |
SYK leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ZBH leads in 1 (Valuation Metrics). 2 tied.
AVNS vs SYK vs ZBH vs MMSI: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AVNS or SYK or ZBH or MMSI a better buy right now?
For growth investors, Merit Medical Systems, Inc.
(MMSI) is the stronger pick with 11. 7% revenue growth year-over-year, versus 1. 9% for Avanos Medical, Inc. (AVNS). Zimmer Biomet Holdings, Inc. (ZBH) offers the better valuation at 23. 5x trailing P/E (9. 8x forward), making it the more compelling value choice. Analysts rate Stryker Corporation (SYK) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AVNS or SYK or ZBH or MMSI?
On trailing P/E, Zimmer Biomet Holdings, Inc.
(ZBH) is the cheapest at 23. 5x versus Stryker Corporation at 35. 0x. On forward P/E, Zimmer Biomet Holdings, Inc. is actually cheaper at 9. 8x.
03Which is the better long-term investment — AVNS or SYK or ZBH or MMSI?
Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.
5%, compared to -47. 3% for Zimmer Biomet Holdings, Inc. (ZBH). Over 10 years, the gap is even starker: MMSI returned +214. 6% versus ZBH's -17. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AVNS or SYK or ZBH or MMSI?
By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.
55β versus Avanos Medical, Inc. 's 1. 54β — meaning AVNS is approximately 182% more volatile than SYK relative to the S&P 500. On balance sheet safety, Avanos Medical, Inc. (AVNS) carries a lower debt/equity ratio of 17% versus 66% for Stryker Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — AVNS or SYK or ZBH or MMSI?
By revenue growth (latest reported year), Merit Medical Systems, Inc.
(MMSI) is pulling ahead at 11. 7% versus 1. 9% for Avanos Medical, Inc. (AVNS). On earnings-per-share growth, the picture is similar: Avanos Medical, Inc. grew EPS 82. 9% year-over-year, compared to -19. 9% for Zimmer Biomet Holdings, Inc.. Over a 3-year CAGR, SYK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AVNS or SYK or ZBH or MMSI?
Stryker Corporation (SYK) is the more profitable company, earning 12.
9% net margin versus -9. 7% for Avanos Medical, Inc. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -8. 8% for AVNS. At the gross margin level — before operating expenses — SYK leads at 64. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AVNS or SYK or ZBH or MMSI more undervalued right now?
On forward earnings alone, Zimmer Biomet Holdings, Inc.
(ZBH) trades at 9. 8x forward P/E versus 24. 8x for Avanos Medical, Inc. — 14. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MMSI: 52. 4% to $95. 00.
08Which pays a better dividend — AVNS or SYK or ZBH or MMSI?
In this comparison, ZBH (1.
1% yield), SYK (1. 1% yield) pay a dividend. AVNS, MMSI do not pay a meaningful dividend and should not be held primarily for income.
09Is AVNS or SYK or ZBH or MMSI better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
55), 1. 1% yield, +187. 1% 10Y return). Avanos Medical, Inc. (AVNS) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, AVNS: -17. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AVNS and SYK and ZBH and MMSI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
SYK, ZBH pay a dividend while AVNS, MMSI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.